

# Supplementary Materials: L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites

Jian Li, Rong Sun, Yuehong Wu, Mingzhu Song, Jia Li, Qianye Yang, Xiaoyi Chen, Jinku Bao and Qi Zhao

**Table S1.** Predicted binding energy of anaplastic lymphoma kinase (ALK)–crizotinib and ALK–lorlatinib complexes.

PDB ID	Mutation	Inhibitor	Ki	IC <sub>50</sub>	AUTODOCK (kJ/mol)	Hawkins_GB/SA (kJ/mol)	MM/PBSA (kJ/mol)
5AA8	C1156Y L1198F	Lorlatinib	61	67	123.7	-77.44	-26.66
5AAB	C1156Y L1198F	Crizotinib	0.6	0.6	25.9	-472.74	-231.88
Folds of change (crizotinib/orlatinib)	C1156Y L1198F	-	111.7	111.7	4.8	6.1	8.7

GB/SA: Generalized Born surface area; MM/PBSA: Molecular mechanics Poisson–Boltzmann surface area; PDB: Protein Data Bank.

**Table S3.** Key amino acid residues contributing to the electrostatic energy.

Position	PDB ID	Electrostatic Energy (kcal/mol)			Folds of Change			Average
		5–10 ns	20–25 ns	25–30 ns	5–10 ns	20–25 ns	25–30 ns	
1124	5AA8	-10.74	-10.98	-10.90	-10.90	6.73	5.74	5.60
	5AAb	-46.58	-73.95	-62.56				
1150	5AA8	-79.38	-69.78	-72.11	1.24	1.08	1.09	1.14
	5AAb	-64.01	-64.55	-66.09				
1119	5AA8	-7.22	-8.98	-8.61	1.26	1.07	1.07	1.14
	5AAb	-9.1	-9.63	-9.25				
1203	5AA8	-1.67	-5.4	-2.28	11.63	3.68	8.28	7.86
	5AAb	-19.42	-19.88	-18.87				
1210	5AA8	4.65	13.43	16.47	2.74	3.82	24.58	8.55
	5AAb	-12.73	3.52	0.67				

**Table S4.** Trends of root-mean-square fluctuation (RMSF) change of the key amino acid residues in ALK.